Sansure Biotech(SH:688289)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥204,847,590.73, a decrease of 85.14% compared to the same period last year[15] - The net profit attributable to shareholders for Q3 2023 was ¥208,047,445.17, down 56.06% year-on-year[15] - Revenue for the reporting period decreased by 85.14% due to a sharp decline in demand for COVID-19 nucleic acid testing reagents and instruments as a result of changes in public health policies[25] - Net profit attributable to shareholders decreased by 56.06% for the reporting period, primarily due to a decline in business revenue[25] - Basic earnings per share for the reporting period decreased by 56.79%, reflecting the decrease in net profit[25] - Net profit for the third quarter of 2023 was RMB 298,485,079.76, a decline of 81.3% compared to RMB 1,598,331,053.82 in Q3 2022[49] - The company reported a total comprehensive income of RMB 289,955,008.79 for the third quarter of 2023, down 82.0% from RMB 1,606,405,928.61 in the same quarter last year[49] - Basic and diluted earnings per share for Q3 2023 were both RMB 0.51, a decrease of 81.3% from RMB 2.74 in Q3 2022[49] Cash Flow and Investments - The net cash flow from investment activities was ¥871,461,461.13, a significant improvement from a negative cash flow of ¥1,084,489,422.23 in the previous year[2] - The net cash flow from operating activities was negative at ¥52,882,403.32, compared to a negative cash flow of ¥169,579,893.12 in the previous year[14] - Cash flow from operating activities showed a net outflow of CNY -169,579,893.12 compared to a net inflow of CNY 1,227,927,781.28 in the previous year, indicating a significant decrease in operational cash generation[39] - The company reported a cash inflow from investment activities of CNY 8,022,320,000.00, an increase from CNY 7,369,998,379.00 year-over-year[39] - The company recorded an investment income of RMB 241,992,279.47 in the first three quarters of 2023, a significant improvement compared to a loss of RMB 15,445,059.41 in the same period of 2022[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥8,307,763,727.79, a decrease of 9.44% from the previous year[14] - The total liabilities amounted to ¥1,660,989,489.00, slightly down from ¥1,664,071,920.76 in the previous year[5] - The equity attributable to shareholders was ¥7,414,741,960.74, a decrease of 1.14% from the previous year[14] - The company's total current assets as of September 30, 2023, amounted to approximately ¥3.46 billion, an increase from ¥3.21 billion as of December 31, 2022[30] - The company’s total liabilities and equity decreased from RMB 9,173,762,083.74 to RMB 8,307,763,727.79 year-over-year[44] - The company's total current liabilities decreased from CNY 1,571,725,748.35 to CNY 771,773,768.27, a reduction of about 50.9%[42] - Long-term equity investments decreased from CNY 294,820,113.30 to CNY 133,083,161.68, a decline of approximately 54.9%[31] Research and Development - Research and development expenses totaled ¥57,430,450.29, representing 28.04% of operating revenue, an increase of 22.31 percentage points year-on-year[14] - Research and development expenses for the first three quarters of 2023 were RMB 137,493,724.89, down 23.6% from RMB 180,146,814.37 in the same period of 2022[46] Shareholder Information - The company has a share repurchase account holding 16,251,077 shares, accounting for 2.76% of total shares[28] - The number of ordinary shareholders at the end of the reporting period was 23,360[33] Other Financial Metrics - The weighted average return on net assets was 2.83%, down 3.51 percentage points from the previous year[14] - The company experienced a foreign exchange gain of RMB 103,622.13 in Q3 2023, compared to a gain of RMB 7,705,723.47 in Q3 2022[49] - The company maintained cash and cash equivalents at ¥3,212,588,702.82, consistent across the reporting periods[52]